FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 329:297-303 July 29, 1993 Number 5 Next

	Full Text Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Zidovudine therapy is of benefit in the treatment of symptomatic and asymptomatic human immunodeficiency virus (HIV) infection in persons with CD4+ cell counts of less than 500 per cubic millimeter. The efficacy, safety, and duration of benefit of zidovudine in those with 500 or more CD4+ cells per cubic millimeter are uncertain.

Methods In a double-blind, placebo-controlled trial, 993 patients with asymptomatic HIV infection and CD4+ cell counts above 400 per cubic millimeter were randomly assigned to receive zidovudine (500 mg twice daily) or placebo for three years. The primary end point was progression of disease, as defined by the development of Centers for Disease Control and Prevention (CDC) group IV disease (including recurrent oral candidiasis, hairy leukoplakia, or progressive diarrhea) or two CD4+ cell counts below 350 per cubic millimeter. This outcome measure was changed from the original end point of the acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex to reflect changes in recommendations for management. The study was terminated after the first interim analysis.

Results Disease progression was significantly less frequent in the zidovudine group (relative risk, 0.56; 95 percent confidence interval, 0.43 to 0.75; P<0.001 by the log-rank test). The probability of disease progression at two years was 0.19 with zidovudine, as compared with 0.34 with placebo (95 percent confidence interval for the difference, -0.21 to -0.08). Progression to CDC group IV disease was reduced by half in the zidovudine recipients (relative risk, 0.49; P = 0.049) and decline in CD4+ cell counts to below 350 per cubic millimeter was reduced by 40 percent (relative risk, 0.60; P<0.001). The inclusion of early HIV disease events (oral candidiasis, oral hairy leukoplakia, and herpes zoster) as end points confirmed the effects of zidovudine on the progression of clinical disease (relative risk, 0.55; 95 percent confidence interval, 0.37 to 0.84; P = 0.004). The median duration of treatment was 94 weeks. Severe hematologic or clinical side effects were rare.

Conclusions Treatment with zidovudine benefits HIV-infected persons with CD4+ cell counts above 400 per cubic millimeter. Despite the use of doses larger than those now generally prescribed, zidovudine was well tolerated for up to three years by most of our patients.

Source Information

From the National Centre in HIV Epidemiology and Clinical Research, St. Vincent's Hospital, University of New South Wales, Sydney, Australia (D.A.C.); Hospital Clinic I Provincial de Barcelona, Barcelona, Spain (J.M.G.); Bispebjerg University Hospital, Copenhagen, Denmark (S.K.); St. Pierre University Hospital, Brussels, Belgium (N.C.); the Wellcome Research Laboratories, Beckenham, Kent, United Kingdom (J.M., J.W.S., A.P.F.); Medizinische Poliklinik der Universitat, Munich, Germany (F.-D.G.); Ulleval University Hospital, Oslo, Norway (J.N.B.); University of Vienna Medical School, Vienna, Austria (G.S.); the Albion Street Centre, Prince of Wales Hospital, Sydney, Australia (R.L.M.); and the Instituto de Salud Carlos III, Madrid (J.G.-L.). A list of the persons and institutions participating in the European-Australian Collaborative Group appears in the Appendix.

Address reprint requests to Dr. Cooper at the National Centre in HIV Epidemiology and Clinical Research, 2nd floor, 376 Victoria St., Sydney NSW 2010, Australia.

Full Text of this Article

Related Letters:

Zidovudine in Asymptomatic HIV Infection
Phillips A. N., Sabin C. A., Berger P. B., Martinez R., Cooper D. A., Gatell J. M.
Extract | Full Text  
N Engl J Med 1993; 329:1895-1896, Dec 16, 1993. Correspondence

More on Zidovudine in Asymptomatic HIV Infection
Altman D. G., Cuzick J., Peto J., Cooper D. A., Gatell J. M.
Extract | Full Text  
N Engl J Med 1994; 330:1758-1759, Jun 16, 1994. Correspondence

This article has been cited by other articles:

• (2005). Additional Information. JAMA 294: E1-E3 [Full Text]  
• Dybul, M., Fauci, A. S., Bartlett, J. G., Kaplan, J. E., Pau, A. K. (2002). Guidelines for Using Antiretroviral Agents among HIV-Infected Adults and Adolescents: The Panel on Clinical Practices for Treatment of HIV. ANN INTERN MED 137: 381-433 [Abstract] [Full Text]  
• Jordan, R., Gold, L., Cummins, C., Hyde, C. (2002). Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. BMJ 324: 757-757 [Abstract] [Full Text]  
• (2001). Five year follow up of vertically HIV infected children in a randomised double blind controlled trial of immediate versus deferred zidovudine: the PENTA 1 trial. Arch. Dis. Child. 84: 230-236 [Abstract] [Full Text]  
• Bucher, H. C., Guyatt, G. H., Cook, D. J., Holbrook, A., McAlister, F. A., for the Evidence-Based Medicine Working Group, (1999). Users' Guides to the Medical Literature: XIX. Applying Clinical Trial Results; A. How to Use an Article Measuring the Effect of an Intervention on Surrogate End Points. JAMA 282: 771-778 [Full Text]  
• Easterbrook, P. J., Goodall, R. L., Babiker, A. G., Yu, L. M., Smith, D., Cooper, D. A., Gazzard, B. G. (1999). Are HIV-infected patients with rapid CD4 cell decline a subgroup who benefit from early antiretroviral therapy?. J Antimicrob Chemother 43: 379-388 [Abstract] [Full Text]  
• Makadon, H. J. (1999). An Asymptomatic 41-Year-Old Man With HIV Infection. JAMA 281: 739-744 [Full Text]  
• Ioannidis, J. P. A. (1998). Effect of the Statistical Significance of Results on the Time to Completion and Publication of Randomized Efficacy Trials. JAMA 279: 281-286 [Abstract] [Full Text]  
• Thomas, S. A., Segal, M. B. (1997). . J. Pharmacol. Exp. Ther. 281: 1211-1218 [Abstract] [Full Text]  
• Hammer, S. M., Katzenstein, D. A., Hughes, M. D., Gundacker, H., Schooley, R. T., Haubrich, R. H., Henry, W. K., Lederman, M. M., Phair, J. P., Niu, M., Hirsch, M. S., Merigan, T. C., The AIDS Clinical Trials Group Study 175 Study Tea, (1996). A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic Millimeter. NEJM 335: 1081-1090 [Abstract] [Full Text]  
• Phillips, A. N, Smith, G. D., Johnson, M. A (1996). For Debate: Will we ever know when to treat HIV infection?. BMJ 313: 608-610 [Full Text]  
• Staszewski, S., Loveday, C., Picazo, J. J., Dellamonica, P., Skinhoj, P., Johnson, M. A., Danner, S. A., Harrigan, P. R., Hill, A. M., Verity, L., McDade, H. (1996). Safety and Efficacy of Lamivudine-Zidovudine Combination Therapy in Zidovudine-Experienced Patients: A Randomized Controlled Comparison With Zidovudine Monotherapy. JAMA 276: 111-117 [Abstract]  
• Moore, R. D., Keruly, J. C., Chaisson, R. E. (1996). Duration of the Survival Benefit of Zidovudine Therapy in HIV Infection. Arch Intern Med 156: 1073-1077 [Abstract]  
• Enger, C., Graham, N., Peng, Y., Chmiel, J. S., Kingsley, L. A., Detels, R., Munoz, A. (1996). Survival From Early, Intermediate, and Late Stages of HIV Infection. JAMA 275: 1329-1334 [Abstract]  
• Laraque, F., Greene, A., Triano-Davis, J. W., Altman, R., Lin-Greenberg, A. (1996). Effect of Comprehensive Intervention Program on Survival of Patients With Human Immunodeficiency Virus Infection. Arch Intern Med 156: 169-176 [Abstract]  
• Cruz, G. D., Lamster, I. B., Begg, M. D., Phelan, J. A., Gorman, J. M., El-Sadr, W. (1996). The Accurate Diagnosis of Oral Lesions in Human Immunodeficiency Virus Infection: Impact on Medical Staging. Arch Otolaryngol Head Neck Surg 122: 68-73 [Abstract]  
• Volberding, P. A., Lagakos, S. W., Grimes, J. M., Stein, D. S., Rooney, J., Meng, T.-C., Fischl, M. A., Collier, A. C., Phair, J. P., Hirsch, M. S., Hardy, W. D., Balfour, H. H., Reichman, R. C., The AIDS Clinical Trials Group, (1995). A Comparison of Immediate with Deferred Zidovudine Therapy for Asymptomatic HIV-Infected Adults with CD4 Cell Counts of 500 or More per Cubic Millimeter. NEJM 333: 401-407 [Abstract] [Full Text]  
• Kinloch-de Loes, S., Hirschel, B. J., Hoen, B., Cooper, D. A., Tindall, B., Carr, A., Saurat, J.-H., Clumeck, N., Lazzarin, A., Mathiesen, L., Raffi, F., Antunes, F., von Overbeck, J., Luthy, R., Glauser, M., Hawkins, D., Baumberger, C., Yerly, S., Perneger, T. V., Perrin, L. (1995). A Controlled Trial of Zidovudine in Primary Human Immunodeficiency Virus Infection. NEJM 333: 408-413 [Abstract] [Full Text]  
• Poznansky, M. C, Coker, R., Skinner, C., Hill, A., Bailey, S., Whitaker, L., Renton, A., Weber, J. (1995). HIV positive patients first presenting with an AIDS defining illness: characteristics and survival. BMJ 311: 156-158 [Abstract] [Full Text]  
• Breckenridge, A. (1995). Recent Advances: Clinical pharmacology and therapeutics. BMJ 310: 377-380 [Full Text]  
• Volberding, P. A., Lagakos, S. W., Grimes, J. M., Stein, D. S., Balfour, H. H. Jr, Reichman, R. C., Bartlett, J. A., Hirsch, M. S., Phair, J. P., Mitsuyasu, R. T., Fischl, M. A., Soeiro, R., the AIDS Clinical Trials Group of the National Ins, , Pettinelli, C. B., Martinez, A. I., Liou, S.-H., Henry, K., Simpson, M., DePaolis-Jones, A., Hewitt, R. G., Blair, D. C., Packard, M. V., Fowler, C., Crumpacker, C. S., Allan, J. D., Fitch, H. F., Dybeck, K., Coleman, R., Jacobson, M., Phair, J. P., Murphy, R., Benson, C., Hardy, W. D., Chafey, S. A., Kruger, S., Reese, J., Dale, E., Harris, C., Steigbigel, N., Becker, R. L., Rexroad, V. E., Feinberg, J. E., Spector, S. A., Richman, D. D., Snyder, R., Merigan, T. C. Jr, Fessel, J., Katzenstein, D., Zachary, J. A., Mushatt, D. M., Hyslop, N. E. Jr, Collier, A. C., Corey, L., Coombs, R. W., Para, M. F., Fass, R. J., Whitacre, C., Sacks, H. S., Mildvan, D., Mendoza, H., Fife, K., Powderly, W. G., Gelb, L. D., Klebert, M., Leedom, J. M., Liggins, M., Quesada, N., Wong, B., Brinkdopke, J., Hoelle, M., Gocke, D. J., McAuliffe, V. J., Valentine, F. T., Dowling, J., Wallace, M., PaulJarrett, V., Cargill, V., McKinley, G. F., Grieco, M. H., Polsky, B., Brown, D. C., van der Horst, C., Fiscus, S., Ragan, D., Cheeseman, S. H., Fairchild, P. G., Lai, K. K., Ho, M., McMahon, D., Armstrong, J. A., Eyster, M. E., Ehmann, W. C., Irwin, D., Steigbigel, R. T., Fuhrer, J., Tenzler, R., Ponticello, L., Giordano, M. F., Murray, H. W. (1994). The Duration of Zidovudine Benefit in Persons With Asymptomatic HIV Infection: Prolonged Evaluation of Protocol 019 of the AIDS Clinical Trials Group. JAMA 272: 437-442 [Abstract]  
• Altman, D. G., Cuzick, J., Peto, J., Cooper, D. A., Gatell, J. M. (1994). More on Zidovudine in Asymptomatic HIV Infection. NEJM 330: 1758-1759 [Full Text]  
• Lundgren, J. D., Phillips, A. N., Pedersen, C., Clumeck, N., Gatell, J. M., Johnson, A. M., Ledergerber, B., Vella, S., Nielsen, J. O., Clumeck, N., DeWit, S., Sommereijns, B., Nielsen, J. O., Lundgren, J., Nielsen, T., Pedersen, C., Jensen, G., Skinhoj, P., Bentsen, K., Gerstoft, J., Melbye, M., Ranki, A., Valle, S.-L., Katlama, C., Berlureau, P., Dietrich, M., Schwander, S., Goebel, F.-D., Kosmidis, J., Stergiou, G., Gouzia, T., Papadopoulos, A., Banhegyi, D., Mulcahy, F., Yust, I., Ben-Ishai, Z., Bentwich, Z., Sacks, T., Maayan, S., Vella, S., Chiesi, A., Ancarani, F., Scalise, G., Bertaggia, A., Francavilla, E., Calonghi, G., Nuova, A. S. M., Emilia, R., Cargnel, A., Arlotti, M., Ciammarughi, R., Colomba, A., DeLalla, F., Fassio, P., Ferlini, A., Fiaccadori, F., Pasetti, G., Giannelli, F., Grillone, W., Lazzarin, A, Monforte, A. D., Mignani, E., Nunnari, A., Ortona, L., Panichi, G., Pauluzzi, S., Piersantelli, N., Ranieri, S., Ricciardiello, P., Roscioli, B., Soranzo, M., Hemmer, R., Danner, S., Bloemkolk, D., Antunes, F., Proenca, R., Gonzalez-Lahoz, J., Martinez-Blanco, L., Clotet, B., Gatell, J., Buira, E., Miro, J., Pehrson, P., Luthy, R., Ledergerber, B., Olsson, K., Glauser, M., Hirschel, B., Johnson, A., Hawkes, S., Phillips, A., Barton, S., Morcinek, J., Pinching, A., Coleman, D., Gjprup, I., Lundgren, J., Nielsen, J., Nieport, C., Pedersen, C., Teglbjaerg, L., Thornval, A. (1994). Comparison of Long-term Prognosis of Patients With AIDS Treated and Not Treated With Zidovudine. JAMA 271: 1088-1092 [Abstract]  
• Saag, M. S. (1994). What to Do When Zidovudine Fails. NEJM 330: 706-707 [Full Text]  
• Phillips, A. N., Sabin, C. A., Berger, P. B., Martinez, R., Cooper, D. A., Gatell, J. M. (1993). Zidovudine in Asymptomatic HIV Infection. NEJM 329: 1895-1896 [Full Text]  
• Sande, M. A., Carpenter, C. C. J., Cobbs, C. G., Holmes, K. K., Sanford, J. P., the National Institute of Allergy and Infectious D, , Sande, M. A., Carpenter, C. C. J., Cobbs, C. G., Coombs, R. W., Fleming, T. R., Holmes, K. K., Denison, R., Gail, M. H., Greaves, W. L., Hirsch, M. S., Luskin-Hawk, R., Mildvan, D., Nelson, C. A., Phair, J. P., Sanford, J. P., Schooley, R., Torres, R. G., Vazquez, R., Deyton, L., Jermano, J., Koziol, J., Pettinelli, C., Katz, D. (1993). Antiretroviral Therapy for Adult HIV-lnfected Patients: Recommendations From a State-of-the-Art Conference. JAMA 270: 2583-2589 [Abstract]  
• Bartlett, J. G. (1993). Zidovudine Now or Later?. NEJM 329: 351-352 [Full Text]